Intravesical mitomycin C for superficial transitional cell carcinoma

References

• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J. Clin.47(1), 5–27 (1997).
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Herr WH. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol. Clin. N. Am.7(1), 137–146 (2000).
   Google Scholar
• Carrion R, Seigne J. Surgical management of bladder carcinoma. Cancer Control9(4), 284–292 (2002).
   PubMedGoogle Scholar
• Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol.175(5), 1641–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. European Association of Urology (EAU) working group on oncological urology. Guidelines on bladder cancer. Eur. Urol.41(2), 105–112 (2002).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Ragnhammar P, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol.40, 371–390 (2001).
   Google Scholar
• Bird VG, Soloway MS, Malmström P-U. Intravesical chemotherapy in the treatment of superficial bladder. In: Bladder Cancer: Current Diagnosis and Treatment. Droller MJ (Ed.). Humana Press, NJ, USA, 183–223 (2001).
   Google Scholar
• Malmstrom PU. Advances in intravesical therapy of urinary bladder cancer. Expert Rev. Anticancer Ther.4(6), 1057–1067 (2004).
   PubMedGoogle Scholar
• Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol.129(3), 505–509 (1983).
   PubMed Web of Science ®Google Scholar
• Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol.161(4), 1120–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Masters JR, Popert RJ, Thompson PM, Gibson D, Coptcoat MJ, Parmar MK. Intravesical chemotherapy with epirubicin: a dose response study. J. Urol.161(5), 1490–1493 (1999).
   PubMed Web of Science ®Google Scholar
• Mazzucchelli R, Barbisan F, Tarquini LM, Streccioni M, Galosi AB. Urothelial changes induced by therapeutic procedures for bladder cancer. A review. Anal. Quant. Cytol. Histol.27(1), 27–34 (2005).
   PubMed Web of Science ®Google Scholar
• Clark T, Chang SS, Cookson MS. Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. J. Urol.167(4), 1795 (2002).
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K et al. (EORTC Genito-Urinary Tract Cancer Collaborative Group). Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
   PubMed Web of Science ®Google Scholar
• Mostafid AH, Rajkumar RGN, Stewart AB, Singh R. Immediate administration of intravesical mitomycin C after tumor resection for superficial bladder cancer. Br. J. Urol. Int.97, 509–512 (2006).
   Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol.168(5), 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette–Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology63(4), 682–686 (2004).
   PubMed Web of Science ®Google Scholar
• Bouffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol.153(3 Pt 2), 934–941 (1995).
   PubMed Web of Science ®Google Scholar
• Clarke NS, Basu S, Prescott S, Puri R. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists. Br. J. Urol. Int.97(4), 716–719 (2006).
   Google Scholar
• Sakamoto N, Naito S, Kumazawa J et al. (Kyushu University Urological Oncology Group). Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int. J. Urol.8(5), 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol.171(6), 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Rintala E, Hellstrom P et al. FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur. Urol.42(2), 167–174 (2002).
   PubMed Web of Science ®Google Scholar
• Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer86(9), 1818–1826 (1999).
   PubMed Web of Science ®Google Scholar
• Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J. Natl Cancer Inst.93(8), 597–604 (2001).
   PubMed Web of Science ®Google Scholar
• Okeke AA, Probert JP, Schwaibold H. Is intravesical chemotherapy for superficial bladder cancer still justified? Br. J. Urol. Int.96, 763–767 (2005).
   Google Scholar
• Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on superficial bladder cancer. J. Urol.156(6), 1934–1940 (1996).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette–Guérin immunotherapy. Am. J. Clin. Oncol.27(5), 522–528 (2004).
   PubMed Web of Science ®Google Scholar
• Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur. Urol.45(6), 730–735 (2004).
   PubMed Web of Science ®Google Scholar
• Melekos MD, Montzouris GD. Intravesical therapy of superficial bladder cancer. Curr. Harm. Des.6(3), 345–359 (2000).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette–Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst. Rev. (3), CD003231 (2003).
   Google Scholar
• Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur. Urol.37(Suppl. 3), 1–9 (2000).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette–Guérin in patients with superficial bladder carcinoma. Swedish–Norwegian Bladder Cancer Study Group. J. Urol.161(4), 1124–1127 (1999).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette–Guérin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. Br. J. Urol. Int.93, 485–490 (2004).
   Google Scholar
• Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am. J. Clin. Oncol26(4), 402–407 (2003).
   PubMed Web of Science ®Google Scholar
• Conrad S, Friedrich MG, Schwaibold H et al. Long term prophylaxis with mitomycin C (MMC) further reduces tumor recurrence compared to short term prophylaxis with MMC or Bacillus Calmette–Guérin (BCG). Presented at: 99th Annual Meeting of the American Urological Association, San Francisco, CA, USA. Publishing ID: 271 (2004).
   Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette–Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol.169(1), 90–95 (2003).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette–Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol.174(1), 86–91 (2005).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette–Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol.163(4), 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Rintala E, Jauhiainen K, Kaasinen E et al. Alternating mitomycin C and bacillius Calmette–Guérin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J. Urol.123, 56–59 (1996).
   Google Scholar
• Kilani RT, Tamimi Y, Karmali S et al. Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs13(6), 557–566 (2002).
   PubMed Web of Science ®Google Scholar
• Witjes JA, Vriesema JL, van der Heijden AG, Peters GJ, Schalken JA. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur. Urol.44(5), 615–619 (2003).
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Gacci M et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology66(4), 726–731 (2005).
   PubMed Web of Science ®Google Scholar
• Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. Br. J. Urol. Int.96(7), 970–976 (2005).
   Google Scholar
• Van der Heijden AG, Witjes JA. Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr. Opin. Urol.13(5), 389–395 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo R, Brausi M, Da Pozzo L et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur. Urol.39(1), 95–100 (2001).
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo L, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol.21(23), 4270–4276 (2003).
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur. Urol.46(1), 65–72 (2004).
   PubMed Web of Science ®Google Scholar
• Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA, Moore RB. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J. Urol.172(5 Pt 1), 2018–2022 (2004).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol.170(3), 777–782 (2003).
   PubMed Web of Science ®Google Scholar
• Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol.7(1), 43–51 (2006).
   PubMed Web of Science ®Google Scholar
• Obek C, Shelfo SW, Korman HJ, Soloway MS. Intravesical therapy for transitional cell carcinoma of the bladder: the community practice. Urology53(1), 82–87 (1999).
   PubMed Web of Science ®Google Scholar
• Bradner WT. Mitomycin C: a clinical update. Cancer Treat. Rev.27(1), 35–50 (2001).
   PubMed Web of Science ®Google Scholar
• Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol. Clin. N. Am.19(3), 529–539 (1992).
   PubMed Web of Science ®Google Scholar
• Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette–Guérin. Participating Clinics. J. Urol.156(3), 962–966 (1996).
   PubMed Web of Science ®Google Scholar
• Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette–Guérin–Tice versus bacillus Calmette–Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin. Urol. Oncol.14(1 Suppl. 1), 10–16 (1996).
   PubMedGoogle Scholar
• Witjes JA, van der Meijden AP, Collette L et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette–Guérin RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology52(3), 403–410 (1998).
   PubMed Web of Science ®Google Scholar
• Regueiro DP, Sanchez SG, Encina JO, Garijo MLR, Bengoechea JM, Baquero GA. Incrusted cystitis after mitomicin-C. Acta Urol. Esp.29(7), 715–718 (2005).
   PubMedGoogle Scholar
• Schenkman E, Lamm DL. Superficial bladder cancer therapy. Sci. World J.4, 387–399 (2004).
   Google Scholar
• Rintala E, Jauhiainen K, Alfthan O et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette–Guérin) in superficial bladder cancer. Eur. Urol.20(1), 19–25 (1991).
   PubMed Web of Science ®Google Scholar
• Kunkeler L, Nieboer C, Bruynzeel DP. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Derm.42(2), 74–76 (2000).
   PubMed Web of Science ®Google Scholar
• Peitsch WK, Klemke CD, Michel MS, Goerdt S, Bayerl C. Hematogenous contact dermatitis after intravesicular instillation of mitomycin C. HautarztDOI: 10.1007/s00105-006-1134-7 (2006) (Epub ahead of print).
   Google Scholar
• Fidalgo A, Lobo L. Allergic contact sensitization from intravesical mitomycin C, without dermatitis. Dermatitis15(3), 161–162 (2004).
   PubMedGoogle Scholar
• Racioppi M, Porreca A, Foschi N, Delicato G, Destito A, D’Addessi A. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Urol. Int.75(4), 373–375 (2005).
   PubMed Web of Science ®Google Scholar
• Neiuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur. Urol.43(6), 711–712 (2003).
   PubMed Web of Science ®Google Scholar
• Oehlschlager S, Loessnitzer A, Froehner M, Hakenberg OW, Manseck A, Wirth MP. Distal ureteral stenosis after early adjuvant intravesical mitomycin C application for superficial bladder cancer. Urol. Int.70(1), 74–76 (2003).
   PubMed Web of Science ®Google Scholar
• Liu CC, Chou YH, Huang CH, Tsai KB. Bladder wall calcification after intravesical chemotherapy with mitomycin C – a case report. Kaohsiung J. Med. Sci.17(5), 274–277 (2001).
   PubMedGoogle Scholar
• Cuervo Pinna MA, Cuervo Pinna C, Macias Castillo S, Bureo Dacal JC, Espada Alonso MJ, Pimentel Leo J. Lung sarcoidosis following instillation of mitomycin C in the urinary bladder. Ann. Med. Int.18(12), 641–643 (2001).
   Google Scholar
• Neulander EZ, Lismer L, Kaneti J. Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin C. J. Urol.164(4), 1306 (2000).
   PubMed Web of Science ®Google Scholar
• Brady JD, Assimos DG, Jordan GH. Urethral slough: a rare and previously unreported complication of intravesical mitomycin. J. Urol.164(4), 1305 (2000).
   PubMed Web of Science ®Google Scholar
• Cliff AM, Romaniuk CS, Parr NJ. Perivesical inflammation after early mitomycin C instillation. Br. J. Urol. Int.85(4), 556–557 (2000).
   Google Scholar
• Oddens JR, van der Meijden AP, Sylvster R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur. Urol.46(3), 336–338 (2004).
   PubMed Web of Science ®Google Scholar
• Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koc A, Akbulut Z. The actual incidence of bladder perforation following transurethral bladder surgery. J. Urol.174(6), 2260–2262 (2005).
   PubMed Web of Science ®Google Scholar
• Yama N, Tsuchida Y, Nuka S et al. Usefulness of magnetic resonance imaging for surgical management of extravasation of an antitumor agent: a case report. Jpn. J. Clin. Oncol.31(3), 122–124 (2001).
   PubMed Web of Science ®Google Scholar
• Drago PC, Badalament RA, Lucas J, Drago JR. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer. J. Urol.142(4), 1071–1072 (1989).
   PubMed Web of Science ®Google Scholar
• Doherty AP, Trendell-Smith N, Stirling R, Rogers H, Bellringer J. Perivesical fat necrosis after adjuvant intravesical chemotherapy. Br. J. Urol. Int.83(4), 420–423 (1999).
   Google Scholar